Does comparative effectiveness have a comparative edge?

JAMA

Volumn 301, Issue 23, 2009, Pages 2488-2490

  Alexander, G Caleb ^a,b   Stafford, Randall S ^c  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO; ROFECOXIB; TEGASEROD; TROGLITAZONE; WARFARIN; DRUG;

ARTIFICIAL HEART PACEMAKER; ASTHMA; AWARENESS; BLOOD PRESSURE MONITORING; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DEMENTIA; DIABETES MELLITUS; EVIDENCE BASED PRACTICE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HEALTH SERVICE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; IRRITABLE COLON; MEDICAL RESEARCH; METABOLIC DISORDER; NOTE; PAIN; PRIORITY JOURNAL; UPPER RESPIRATORY TRACT INFECTION; APPARATUS, EQUIPMENT AND SUPPLIES; ARTICLE; CLINICAL MEDICINE; ECONOMICS; HEALTH SERVICES RESEARCH; MANAGEMENT; UNITED STATES;

CLINICAL MEDICINE; ECONOMICS; EQUIPMENT AND SUPPLIES; HEALTH SERVICES RESEARCH; PHARMACEUTICAL PREPARATIONS; POLICY MAKING; UNITED STATES;

EID: 67649226035     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2009.851     Document Type: Note

References (14)

1. US House Appropriations Committee. American Recovery and Reinvestment Act of 2009 (Title IX, Subtitle B, Sec. 9201), HR, 111th Cong, 1st Sess (2009). http://appropriations.house.gov/pdf/RecoveryBill01-15-09.pdf. Accessed May 22, 2009.
2. Deyo RA. Gaps, tensions, and conflicts in the FDA approval process: implications for clinical practice. J Am Board Fam Pract. 2004;17(2):142-149.
3. Domino ME, Swartz MS. Who are the new users of antipsychotic medications? Psychiatr Serv. 2008;59(5):507-514.
4. Davies LM, Lewis S, Jones PB, et al; CUtLASS Team. Cost-effectiveness of firstv second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy. Br J Psychiatry. 2007;191:14-22.
5. Dai C, Stafford RS, Alexander GC. National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation. Arch Intern Med. 2005;165(2):171-177.
6. Goodwin JS, Goodwin JM. The tomato effect: rejection of highly efficacious therapies. JAMA. 1984;251(18):2387-2390.
7. Coleman JS, Katz E, Mentzel H. Medical Innovation: Diffusion of a Medical Drug Among Doctors. Indianapolis, IN: Bobbs-Merrill; 1966.
8. Redelmeier DA, Cialdini RB. Problems for clinical judgment: 5, principles of influence in medical practice. CMAJ. 2002;166(13):1680-1684.
9. Plassmann H, O'Doherty J, Shiv B, Rangel A. Marketing actions can modulate neural representations of experienced pleasantness. Proc Natl Acad Sci USA. 2008;105(3):1050-1054.
10. Chernew ME, Jacobson PD, Hofer TP, Aaronson KD, Fendrick AM. Barriers to constraining health care cost growth. Health Aff (Millwood). 2004;23(6):122-128.
11. Berwick D. A user's manual for the IOM's "Quality Chasm" Report. Health Aff (Millwood). 2002;21(3):80-90.
12. Committee on the Assessment of the US Drug Safety System. The Future of Drug Safety: Promoting and Protecting the Health of the Public. Baciu A, Stratton K, Burke SP, eds. Washington, DC: National Academies Press; 2006.
13. US Department of Health and Human Services. The Sentinel Initiative: a national strategy for monitoring medical product safety. US Food and Drug Administration Web site. http://www.fda.gov/oc/initiatives/advance/reports/ report0508.html. Accessed March 9, 2009.
14. American College of Physicians. Information on cost-effectiveness: an essential product of a national comparative effectiveness program. Ann Intern Med. 2008;148(12):956-961.